GSK (NYSE:GSK) vs. Clene (NASDAQ:CLNN) Financial Review

Clene (NASDAQ:CLNN) and GSK (NYSE:GSK) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Clene and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
GSK	14.56%	43.23%	11.60%

Risk & Volatility

Clene has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Institutional & Insider Ownership

23.3% of Clene shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Clene and GSK”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200,000.00	247.36	-$26.17 million	($3.50)	-1.10
GSK	$43.07 billion	2.34	$7.54 billion	$3.20	15.59

GSK has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Clene and GSK, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1	0	6	0	2.71
GSK	2	6	1	1	2.10

Clene presently has a consensus price target of $33.25, suggesting a potential upside of 763.64%. GSK has a consensus price target of $53.00, suggesting a potential upside of 6.26%. Given Clene’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Clene is more favorable than GSK.

Summary

GSK beats Clene on 8 of the 15 factors compared between the two stocks.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.